NCT00857311 - MRKAd5 HIV-1 Gag Vaccine (V520) in Subjects With Chronic Hepatitis C (V520-022) (COMPLETED) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2004

Primary Completion Date

January 31, 2006

Study Completion Date

May 31, 2010

Conditions

Hepatitis C

Interventions

BIOLOGICAL

MRKAd5 HIV-1 gag vaccine (V520)

3-dose prime boosting regimen of 1.0-mL intramuscular injections of 1x10\^9 viral particles/dose of MRKAd5 HIV-1 gag vaccine (V520) at Day 1 and Weeks 4 and 26

BIOLOGICAL

Comparator: Placebo

1.0 mL intramuscular injection of Placebo at Day 1 and Weeks 4 and 26

BIOLOGICAL

Comparator: Open Label Tetanus and Diptheria Toxoids Adsorbed

0.5 mL Open Label Tetanus and Diptheria Toxoids Adsorbed (Td) intramuscular injection at Day 1 only

BIOLOGICAL

MRKAd5 HIV-1 gag vaccine (V520)

3-dose prime boosting regimen of 1.0-mL intramuscular injections of 1x10\^10 viral particles/dose of MRKAd5 HIV-1 gag vaccine (V520) at Day 1 and Weeks 4 and 26

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY